BPC-157 and KPV are supplied strictly as laboratory research materials. They are not approved, intended or authorised for human consumption or any therapeutic use in this context. This article is written for qualified researchers and is not medical advice.
Repair versus resolution
Ask why BPC-157 and KPV are so often mentioned in the same breath and the answer is the gut. Both peptides sit at the centre of gastrointestinal and inflammation research, and both are unusual for retaining bioactivity in conditions that destroy most peptides. But their mechanisms pull in different directions. BPC-157 is a tissue-repair and angiogenesis compound — it builds new vascular supply and drives the cellular machinery of healing. KPV is a receptor-independent anti-inflammatory — it quietens the transcriptional programme that produces pro-inflammatory cytokines in the first place. One rebuilds; the other calms. That contrast is exactly why researchers tend to look at them side by side rather than as substitutes.
| BPC-157 | KPV | |
|---|---|---|
| Class / peptide type | Synthetic pentadecapeptide (gastric-juice fragment) | Synthetic tripeptide (α-MSH C-terminal fragment) |
| Primary mechanism | VEGFR2 upregulation, angiogenesis, FAK-paxillin & JAK2/STAT3 signalling | Intracellular NF-κB inhibition after PEPT1/PEPT2 uptake |
| Structure / MW | 15 amino acids · ~1419 Da | 3 amino acids (Lys-Pro-Val) · ~342 Da |
| Receptor engagement | Pathway-mediated (VEGFR2 and downstream axes) | Receptor-independent · MC1R-sparing |
| Main research focus | Tissue repair, GI cytoprotection, musculoskeletal, CNS | IBD/colitis, dermal inflammation, wound healing |
| Typical pairing / stack | Studied with TB-500, GHK-Cu (KLOW-type repair blends) | Component of the KLOW blend (with TB-500, BPC-157, GHK-Cu) |
| Regulatory status | Unapproved · FDA Category 2 (2023) · WADA-prohibited | Unapproved · unregulated research compound |
BPC-157: the repair pentadecapeptide
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15-amino-acid fragment derived from a protein isolated in human gastric juice. It is one of the most heavily studied tissue-repair peptides in the preclinical literature, with more than three decades of published work spanning musculoskeletal tissue, the gastrointestinal system, vascular biology and the central nervous system.
Mechanistically, the peptide's signature is angiogenesis. It upregulates the VEGFR2 receptor, promoting the formation of new blood vessels in injured tissue — a rate-limiting step in repair. Alongside that, it activates the FAK-paxillin and JAK2/STAT3 pathways that govern fibroblast migration, proliferation and extracellular-matrix synthesis, and it modulates nitric oxide while suppressing pro-inflammatory cytokines such as TNF-α. A defining practical feature is its acid stability: BPC-157 is not readily degraded by stomach acid, which is unusual for a peptide of its class and underpins much of the interest in its gastrointestinal activity. In colitis and gastric-lesion models it has been studied for cytoprotection and preserved mucosal integrity. Researchers sourcing material can buy BPC-157 UK at research grade with a COA; the full mechanism write-up lives on our BPC-157 knowledgebase page.
KPV: the minimal anti-inflammatory fragment
KPV is a synthetic tripeptide corresponding to the C-terminal three residues — lysine, proline and valine, positions 11-13 — of α-melanocyte-stimulating hormone (α-MSH). Despite its minimal size, it retains the anti-inflammatory and antimicrobial activity of the full-length hormone while shedding the pigmentation and central effects that come with melanocortin-receptor engagement.
Its mechanism is where the contrast with BPC-157 is sharpest. KPV enters cells through the PEPT1 and PEPT2 oligopeptide transporters and acts intracellularly, inhibiting NF-κB — the master transcription factor for pro-inflammatory cytokine programmes. The result is suppressed production of TNF-α, IL-1β, IL-6 and chemokines from activated immune cells. Crucially, this activity is receptor-independent and MC1R-sparing: KPV does not meaningfully engage melanocortin receptors, so it avoids the pigmentation, cardiovascular and CNS effects of larger α-MSH analogues. Because PEPT1 is the principal peptide transporter of the small intestine, KPV is one of the few peptides that retains bioactivity after oral administration — the basis for its prominence in inflammatory bowel disease models, alongside dermal and wound-healing research. It also features in the four-compound KLOW blend. Material to buy KPV UK is available at ≥99% purity, and the mechanism detail sits on our KPV knowledgebase page.
What the differences mean in a research context
The cleanest way to hold these two apart is by the question each one answers. BPC-157 speaks to repair: can new vascular supply and matrix synthesis be driven in damaged tissue? Its VEGFR2-led angiogenesis and connective-tissue signalling make it a broad repair reagent studied well beyond the gut — in tendon, ligament, muscle and CNS models. KPV speaks to inflammation: can the cytokine programme be turned down at source? Its intracellular NF-κB inhibition is narrower and more targeted, and its lack of receptor engagement means fewer off-pathway variables to account for in a study design.
Their structures reflect that split. BPC-157 is a 15-residue peptide of roughly 1419 Da carrying multiple signalling functions; KPV is a three-residue fragment of around 342 Da doing essentially one thing well. Both, unusually, survive the gut — BPC-157 through intrinsic acid stability, KPV through active PEPT1 transport — which is why both keep appearing in gastrointestinal work and why the "repair versus anti-inflammatory" framing is not academic. In a colitis or mucosal-integrity model the two mechanisms are complementary rather than competing, which is the logic behind stacking them: KPV suppresses the inflammatory signal while BPC-157 supports the repair response. That complementarity is visible in the KLOW blend, where KPV and BPC-157 sit alongside TB-500 and GHK-Cu.
On status, both remain unapproved research compounds and neither has been evaluated by the MHRA or FDA. BPC-157 additionally carries specific flags — it was added to the FDA's Category 2 compounding list in 2023 and is prohibited under WADA regulations — while KPV is best described as an unregulated research-grade compound. In every case the framing is the same: in vitro research use only, not for human consumption.
The bottom line
BPC-157 and KPV are not rivals so much as two halves of a gut-and-inflammation research toolkit. BPC-157 is the broad repair and angiogenesis pentadecapeptide; KPV is the minimal, receptor-independent anti-inflammatory tripeptide. Choose by the mechanism your model needs — or study them together, as much of the literature does. For research-grade material, see our dedicated pages to buy BPC-157 UK and buy KPV UK, each ≥99% purity with a COA.